Pharmala Biotech Holdings Valuation

PMBHFDelisted Stock   0.25  0.00  0.00%   
the company is overvaluedPharmala Biotech Holdings holds a recent Real Value of USD0.22 per share. The prevailing price of the company is USD0.25.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Pharmala Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Pharmala Biotech and how it compares across the competition.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Consideration for investing in Pharmala Pink Sheet

If you are still planning to invest in Pharmala Biotech Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pharmala Biotech's history and understand the potential risks before investing.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance